AKUMS - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.2
| Stock Code | AKUMS | Market Cap | 7,597 Cr. | Current Price | 483 ₹ | High / Low | 623 ₹ |
| Stock P/E | 59.8 | Book Value | 151 ₹ | Dividend Yield | 0.00 % | ROCE | 16.2 % |
| ROE | 13.2 % | Face Value | 2.00 ₹ | DMA 50 | 467 ₹ | DMA 200 | 485 ₹ |
| Chg in FII Hold | -1.13 % | Chg in DII Hold | 5.13 % | PAT Qtr | 31.0 Cr. | PAT Prev Qtr | 23.5 Cr. |
| RSI | 53.4 | MACD | 3.36 | Volume | 1,35,088 | Avg Vol 1Wk | 1,24,846 |
| Low price | 405 ₹ | High price | 623 ₹ | PEG Ratio | 1.75 | Debt to equity | 0.02 |
| 52w Index | 36.0 % | Qtr Profit Var | -24.7 % | EPS | 7.88 ₹ | Industry PE | 27.2 |
Analysis: AKUMS has moderate fundamentals with ROE at 13.2% and ROCE at 16.2%, supported by a nearly debt-free balance sheet (Debt-to-equity 0.02). EPS of ₹7.88 is modest relative to price, and dividend yield is 0%, offering no income return. Valuations are stretched with a P/E of 59.8 compared to industry average of 27.2, and PEG ratio of 1.75 indicates moderately expensive growth. Technicals are neutral-to-positive with RSI at 53.4 and MACD slightly positive, suggesting short-term stability. Overall, fundamentals are fair but valuations limit long-term attractiveness.
Entry Zone: Ideal accumulation range is ₹460–₹480, near DMA 50 (₹467) and DMA 200 (₹485), providing margin of safety against current valuations.
Exit Strategy: If already holding, maintain a medium-term horizon (2–4 years) as ROCE supports moderate compounding. Consider partial profit booking near ₹600–₹620 resistance levels. Monitor quarterly profit trends and valuation multiples closely.
Positive
- ROCE at 16.2% and ROE at 13.2% show moderate efficiency.
- Debt-to-equity at 0.02 indicates virtually debt-free balance sheet.
- PAT growth from ₹23.5 Cr. to ₹31 Cr. quarter-on-quarter shows earnings improvement.
- DII holding increased (+5.13%), reflecting strong domestic institutional confidence.
Limitation
- High P/E (59.8) compared to industry average (27.2).
- PEG ratio (1.75) signals moderately expensive growth.
- EPS of ₹7.88 is modest relative to price.
- Dividend yield at 0% offers no income return.
- Quarterly profit variation (-24.7%) shows earnings volatility.
Company Negative News
- Decline in FII holding (-1.13%) shows reduced foreign investor confidence.
Company Positive News
- Increase in DII holding (+5.13%) reflects strong domestic institutional support.
- MACD positive (3.36) indicates improving technical momentum.
Industry
- Industry P/E at 27.2 suggests moderate sector valuation.
- Pharma sector benefits from long-term demand in healthcare and exports.
Conclusion
AKUMS is a moderately attractive candidate for medium-term investment with fair ROE/ROCE and a debt-free balance sheet. Best suited for accumulation near ₹460–₹480. Existing holders should maintain a 2–4 year horizon, booking profits near resistance levels while monitoring valuation risks and quarterly earnings trends.
Would you like me to extend this into a peer benchmarking overlay with other mid-cap pharma companies, so you can compare AKUMS against sector peers on ROE, ROCE, PEG, and valuation multiples for margin-of-safety clarity?